Ketamine administration during the second postnatal week induces enduring schizophrenia-like behavioral symptoms and reduces parvalbumin expression in the medial prefrontal cortex of adult mice

Behavioural Brain Research

Volumn 282, Issue , 2015, Pages 165-175

  Jeevakumar, Vivek ^a   Driskill, Christopher ^a   Paine, Alyssa ^a   Sobhanian, Millad ^a   Vakil, Haris ^a   Morris, Brett ^a   Ramos, Jeremiah ^a   Kroener, Sven ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Ketamine; NMDAR; Parvalbumin; Perinatal; Prefrontal cortex; Schizophrenia

Indexed keywords

AMPHETAMINE; KETAMINE; PARVALBUMIN; AMINO ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTIONAL SET SHIFT TASK; CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; EXPERIMENTAL BEHAVIORAL TEST; EXPERIMENTAL HYPERACTIVITY; LATENT INHIBITION TASK; MALE; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TASK; PERINATAL PERIOD; PREFRONTAL CORTEX; PROTEIN EXPRESSION; SCHIZOPHRENIA; SOCIAL INTERACTION TEST; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; BEHAVIOR; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; INBRED MOUSE STRAIN; METABOLISM; PSYCHOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; BEHAVIORAL SYMPTOMS; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MALE; MICE; MICE, INBRED STRAINS; PARVALBUMINS; PREFRONTAL CORTEX; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84921495017     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.01.010     Document Type: Article

References (111)

1. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301-1308.
2. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17:141-150.
3. Krystal J.H., Anand A., Moghaddam B. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry 2002, 59:663-664.
4. Amitai N., Semenova S., Markou A. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology (Berl) 2007, 193:521-537.
5. Amitai N., Markou A. Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration. Psychopharmacology (Berl) 2009, 202:275-286.
6. Coleman L.G., Jarskog L.F., Moy S.S., Crews F.T. Deficits in adult prefrontal cortex neurons and behavior following early post-natal NMDA antagonist treatment. Pharmacol Biochem Behav 2009, 93(3):322-330.
7. Chatterjee M., Ganguly S., Srivastava M., Palit G. Effect of chronic versus acute ketamine administration and its withdrawal effect on behavioural alterations in mice: implications for experimental psychosis. Behav Brain Res 2011, 216:247-254.
8. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13:9-19.
9. Cochran S.M., Kennedy M., McKerchar C.E., Steward L.J., Pratt J.A., Morris B.J. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 2003, 28:265-275.
10. Abekawa T., Ito K., Nakagawa S., Koyama T. Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats. Psychopharmacology (Berl) 2007, 192:303-316.
11. Braun I., Genius J., Grunze H., Bender A., Möller H.-J., Rujescu D. Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. Schizophr Res 2007, 97:254-263.
12. Eyles D.W., McGrath J.J., Reynolds G.P. Neuronal calcium-binding proteins and schizophrenia. Schizophr Res 2002, 57:27-34.
13. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005, 6:312-324.
14. Akbarian S., Huang H.S. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev 2006, 52:293-304.
15. Sohal V.S., Zhang F., Yizhar O., Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 2009, 459:698-702.
16. Carlén M., Meletis K., Siegle J.H., Cardin J.A., Futai K., Vierling-Claassen D., et al. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol Psychiatry 2012, 17:537-548.
17. Pantelis C., Barber F.Z., Barnes T.R., Nelson H.E., Owen A.M., Robbins T.W. Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 1999, 37:251-270.
18. Weiss A.P., Heckers S. Neuroimaging of declarative memory in schizophrenia. Scand J Psychol 2001, 42:239-250.
19. File S.E., Seth P. A review of 25 years of the social interaction test. Eur J Pharmacol 2003, 463:35-53.
20. Pallanti S., Cantisani A., Grassi G. Anxiety as a core aspect of schizophrenia. Curr Psychiatry Rep 2013, 15:354.
21. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
22. Wang H.X., Gao W.J. Prolonged exposure to NMDAR antagonist induces cell-type specific changes of glutamatergic receptors in rat prefrontal cortex. Neuropharmacology 2012, 62:1808-1822.
23. Nikiforuk A., Kos T., Fijal K., Holuj M., Rafa D., Popik P. Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS ONE 2013, 8:e66695.
24. Weinberger D.R. On the plausibility of the neurodevelopmental hypothesis of schizophrenia. Neuropsychopharmacology 1996, 14:1S-11S.
25. Lewis D.A., Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000, 28:325-334.
26. Waites C.L., Craig A.M., Garner C.C. Mechanisms of vertebrate synaptogenesis. Annu Rev Neurosci 2005, 28:251-274.
27. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010, 13:76-83.
28. Jeevakumar V., Kroener S. Ketamine administration during the second postnatal week alters synaptic properties of fast-spiking interneurons in the medial prefrontal cortex of adult mice. Cereb Cortex 2014, 10.1093/cercor/bhu293.
29. Boctor S.Y., Ferguson S.A. Neonatal NMDA receptor antagonist treatments have no effects on prepulse inhibition of postnatal day 25 Sprague-Dawley rats. Neurotoxicology 2009, 30:151-154.
30. Nakatani-Pawlak A., Yamaguchi K., Tatsumi Y., Mizoguchi H., Yoneda Y. Neonatal phencyclidine treatment in mice induces behavioral, histological and neurochemical abnormalities in adulthood. Biol Pharm Bull 2009, 32:1576-1583.
31. Kaalund S.S., Riise J., Broberg B.V., Fabricius K., Karlsen A.S., Secher T., et al. Differential expression of parvalbumin in neonatal phencyclidine-treated rats and socially isolated rats. J Neurochem 2013, 124:548-557.
32. Powell S.B., Sejnowski T.J., Behrens M.M. Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia. Neuropharmacology 2012, 62:1322-1331.
33. Chattopadhyaya B., Di Cristo G., Higashiyama H., Knott G.W., Kuhlman S.J., Welker E., et al. Experience and activity-dependent maturation of perisomatic GABAergic innervation in primary visual cortex during a postnatal critical period. J Neurosci 2004, 24:9598-9611.
34. Kroener S., Mulholland P.J., New N.N., Gass J.T., Becker H.C., Chandler L.J. Chronic alcohol exposure alters behavioral and synaptic plasticity of the rodent prefrontal cortex. PLoS ONE 2012, 7:e37541.
35. Bethus I., Lemaire V., Lhomme M., Goodall G. Does prenatal stress affect latent inhibition? It depends on the gender. Behav Brain Res 2005, 158:331-338.
36. Rompala G.R., Zsiros V., Zhang S., Kolata S.M., Nakazawa K. Contribution of NMDA receptor hypofunction in prefrontal and cortical excitatory neurons to schizophrenia-like phenotypes. PLoS ONE 2013, 8:e61278.
37. Behrens M.M., Ali S.S., Dao D.N., Lucero J., Shekhtman G., Quick K.L., et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 2007, 318:1645-1647.
38. Zhang Y., Behrens M.M., Lisman J.E. Prolonged exposure to NMDAR antagonist suppresses inhibitory synaptic transmission in prefrontal cortex. J Neurophysiol 2008, 100:959-965.
39. Hikida T., Jaaro-Peled H., Seshadri S., Oishi K., Hookway C., Kong S., et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci 2007, 104:14501-14506.
40. Lodge D.J., Behrens M.M., Grace A.A. A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci 2009, 29:2344-2354.
41. Lubow R.E., Weiner I., Schlossberg A., Baruch I. Latent inhibition and schizophrenia. Bull Psychonom Soc 1987, 25:464-467.
42. Weiner I. Neural substrates of latent inhibition: the switching model. Psychol Bull 1990, 108:442-461.
43. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007, 27:11496-11500.
44. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997, 17:2921-2927.
45. Adams B., Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 1998, 18:5545-5554.
46. Gunduz-Bruce H. The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res Rev 2009, 60:279-286.
47. Narendran R., Frankle W.G., Keefe R., Gil R., Martinez D., Slifstein M., et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry 2005, 162:2352-2359.
48. Tsukada H., Nishiyama S., Fukumoto D., Sato K., Kakiuchi T., Domino E.F. Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology 2005, 30:1861-1869.
49. Bayer S.A., Altman J., Russo R.J., Zhang X. Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 1993, 14:83-144.
50. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010, 167:261-280.
51. Ikonomidou C., Mosinger J.L., Salles K.S., Labruyere J., Olney J.W. Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-aspartate neurotoxicity. J Neurosci 1989, 9:2809-2818.
52. Wang H.X., Gao W.J. Cell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex. Neuropsychopharmacology 2009, 34:2028-2040.
53. Zhang Z., Sun Q.Q. Development of NMDA NR2 subunits and their roles in critical period maturation of neocortical GABAergic interneurons. Dev Neurobiol 2011, 71:221-245.
54. Lewis D.A., Curley A.A., Glausier J.R., Volk D.W. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 2012, 35:57-67.
55. Uehara T., Sumiyoshi T., Seo T., Matsuoka T., Itoh H., Kurachi M. T-817MA, but not haloperidol and risperidone, restores parvalbumin-positive γ-aminobutyric acid neurons in the prefrontal cortex and hippocampus of rats transiently exposed to MK-801 at the neonatal period. ISRN Psychiatry 2012, 2012:947149.
56. Beasley C.L., Reynolds G.P. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 1997, 24:349-355.
57. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008, 31:234-242.
58. Winterer G., Weinberger D.R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci 2004, 27:683-690.
59. Cho R.Y., Konecky R.O., Carter C.S. Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. Proc Natl Acad Sci 2006, 103:19878-19883.
60. Minzenberg M.J., Firl A.J., Yoon J.H., Gomes G.C., Reinking C., Carter C.S. Gamma oscillatory power is impaired during cognitive control independent of medication status in first-episode schizophrenia. Neuropsychopharmacology 2010, 35:2590-2599.
61. Green M.F., Kern R.S., Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004, 72:41-51.
62. Stefani M.R., Moghaddam B. Transient N-methyl-d-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiatry 2005, 57(4):433-436.
63. Broberg B.V., Dias R., Glenthoj B.Y., Olsen C. Evaluation of a neurodevelopmental model of schizophrenia-early postnatal PCP treatment in attentional set-shifting. Behav Brain Res 2008, 190:160-163.
64. Goldberg T.E., Weinberger D.R. Probing prefrontal function in schizophrenia with neuropsychological paradigms. Schizophr Bull 1988, 14:179-183.
65. Nikiforuk A., Gołembiowska K., Popik P. Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats. Eur Neuropsychopharmacol 2010, 20:37-48.
66. Neill J.C., Barnes S., Cook S., Grayson B., Idris N.F., McLean S.L., et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 2010, 128:419-432.
67. Kos T., Nikiforuk A., Rafa D., Popik P. The effects of NMDA receptor antagonists on attentional set-shifting task performance in mice. Psychopharmacology (Berl) 2011, 214:911-921.
68. Gastambide F., Mitchell S.N., Robbins T.W., Tricklebank M.D., Gilmour G. Temporally distinct cognitive effects following acute administration of ketamine and phencyclidine in the rat. Eur Neuropsychopharmacol 2013, 23:1414-1422.
69. Birrell J.M., Brown V.J. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 2000, 20:4320-4324.
70. Floresco S.B., Magyar O., Ghods-Sharifi S., Vexelman C., Tse M.T.L. Multiple dopamine receptor subtypes in the medial prefrontal cortex of the rat regulate set-shifting. Neuropsychopharmacology 2006, 31:297-309.
71. Owen A.M., Roberts A.C., Polkey C.E., Sahakian B.J., Robbins T.W. Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 1991, 29:993-1006.
72. Dias R., Robbins T.W., Roberts A.C. Dissociable forms of inhibitory control within prefrontal cortex with an analog of the Wisconsin Card Sort Test: restriction to novel situations and independence from on-line processing. J Neurosci 1997, 17:9285-9297.
73. Ragozzino M.E. The effects of dopamine D(1) receptor blockade in the prelimbic-infralimbic areas on behavioral flexibility. Learn Mem 2002, 9:18-28.
74. Roberts B.M., Seymour P.A., Schmidt C.J., Williams G.V., Castner S.A. Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. Psychopharmacology (Berl) 2010, 210:407-418.
75. Greco B., Carli M. Reduced attention and increased impulsivity in mice lacking NPY Y2 receptors: relation to anxiolytic-like phenotype. Behav Brain Res 2006, 169:325-334.
76. Engin E., Treit D., Dickson C.T. Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience 2009, 161:359-369.
77. Parise E.M., Alcantara L.F., Warren B.L., Wright K.N., Hadad R., Sial O.K., et al. Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats. Biol Psychiatry 2013, 74:750-759.
78. Mejia-Toiber J., Boutros N., Markou A., Semenova S. Impulsive choice and anxiety-like behavior in adult rats exposed to chronic intermittent ethanol during adolescence and adulthood. Behav Brain Res 2014, 266:19-28.
79. Moser P.C., Hitchcock J.M., Lister S., Moran P.M. The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Brain Res Rev 2000, 33:275-307.
80. Swerdlow N.R., Braff D.L., Hartston H., Perry W., Geyer M.A. Latent inhibition in schizophrenia. Schizophr Res 1996, 20:91-103.
81. Solomon P.R., Crider A., Winkelman J.W., Turi A., Kamer R.M., Kaplan L.J. Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder. Biol Psychiatry 1981, 16:519-537.
82. Weiner I., Lubow R.E., Feldon J. Chronic amphetamine and latent inhibition. Behav Brain Res 1981, 2:285-286.
83. Weiner I., Feldon J. The switching model of latent inhibition: an update of neural substrates. Behav Brain Res 1997, 88:11-25.
84. Escobar M., Oberling P., Miller R.R. Associative deficit accounts of disrupted latent inhibition and blocking in schizophrenia. Neurosci Biobehav Rev 2002, 26:203-216.
85. Cirillo M.A., Seidman L.J. Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms. Neuropsychol Rev 2003, 13:43-77.
86. Ragland J.D., Laird A.R., Ranganath C., Blumenfeld R.S., Gonzales S.M., Glahn D.C. Prefrontal activation deficits during episodic memory in schizophrenia. Am J Psychiatry 2009, 166:863-874.
87. Stone W.S., Hsi X. Declarative memory deficits and schizophrenia: problems and prospects. Neurobiol Learn Mem 2011, 96:544-552.
88. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 1988, 31:47-59.
89. Antunes M., Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process 2012, 13:93-110.
90. Goulart B.K., de Lima M.N., de Farias C.B., Reolon G.K., Almeida V.R., Quevedo J., et al. Ketamine impairs recognition memory consolidation and prevents learning-induced increase in hippocampal brain-derived neurotrophic factor levels. Neuroscience 2010, 167:969-973.
91. Seamans J.K., Floresco S.B., Phillips A.G. Functional differences between the prelimbic and anterior cingulate regions of the rat prefrontal cortex. Behav Neurosci 1995, 109:1063-1073.
92. Barker G.R.I., Bird F., Alexander V., Warburton E.C. Recognition memory for objects, place, and temporal order: a disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex. J Neurosci 2007, 27:2948-2957.
93. De Lima M.N., Laranja D.C., Bromberg E., Roesler R., Schroder N. Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav Brain Res 2005, 156:139-143.
94. Snigdha S., Horiguchi M., Huang M., Li Z., Shahid M., Neill J.C., et al. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs receptor inverse agonist 2010, 332:622-631.
95. Gaskin P.L.R., Alexander S.P.H., Fone K.C.F. Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of schizophrenia-like behaviour in the rat. Psychopharmacology (Berl) 2014, 231:2533-2545.
96. Millan M.J., Fone K., Steckler T., Horan W.P. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol 2014, 24:645-692.
97. Sams-Dodd F. Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Psychopharmacology (Berl) 1998, 135:182-193.
98. Becker A., Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:1267-1277.
99. Georgiadou G., Grivas V., Tarantilis P.A., Pitsikas N. Crocins, the active constituents of Crocus sativus L., counteracted ketamine-induced behavioural deficits in rats. Psychopharmacology (Berl) 2014, 231:717-726.
100. Terranova J.P., Chabot C., Barnouin M.C., Perrault G., Depoortere R., Griebel G., et al. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology (Berl) 2005, 181:134-144.
101. Harich S., Gross G., Bespalov A. Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl) 2007, 192:511-519.
102. Pichat P., Bergis O.E., Terranova J.-P., Urani A., Duarte C., Santucci V., et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 2007, 32:17-34.
103. Amani M., Samadi H., Doosti M.-H., Azarfarin M., Bakhtiari A., Majidi-Zolbanin N., et al. Neonatal NMDA receptor blockade alters anxiety- and depression-related behaviors in a sex-dependent manner in mice. Neuropharmacology 2013, 73:87-97.
104. Lodge D.J., Grace A.A. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci 2007, 27:11424-11430.
105. Mouri A., Noda Y., Enomoto T., Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 2007, 51:173-184.
106. Balla A., Sershen H., Serra M., Koneru R., Javitt D.C. Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release. Neuropsychopharmacology 2003, 28:34-44.
107. Uehara T., Sumiyoshi T., Seo T., Matsuoka T., Itoh H., Suzuki M., et al. Neonatal exposure to MK-801, an N-methyl-d-aspartate receptor antagonist, enhances methamphetamine-induced locomotion and disrupts sensorimotor gating in pre- and postpubertal rats. Brain Res 2010, 1352:223-230.
108. Van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 2010, 36:246-270.
109. Lodge D.J., Grace A.A. Developmental pathology, dopamine, stress and schizophrenia. Int J Dev Neurosci 2011, 29:207-213.
110. Nakazawa K., Zsiros V., Jiang Z., Nakao K., Kolata S., Zhang S., et al. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012, 62:1574-1583.
111. Fiedler A., Grecksch G., Reinhold A., Schraven B., Becker A. Hippocampus-dependent learning in SKAP-HOM deficient mice. Behav Brain Res 2014, 270:125-130.